TSMC Dominance Faces Challenge from New Competitor Rapidus in Advanced Chip Manufacturing
Finance

TSMC Dominance Faces Challenge from New Competitor Rapidus in Advanced Chip Manufacturing

authorBy Robert Kiyosaki
DateJul 10, 2026
Read time3 min

Taiwan Semiconductor Manufacturing Company (TSMC) has consistently been a leader in the infrastructure supporting artificial intelligence. Renowned as the world's foremost chip foundry, TSMC produces sophisticated semiconductors for industry giants such as Nvidia, Advanced Micro Devices, and Broadcom, among others. The company commands an impressive 73% share of the global foundry market, significantly dwarfing its closest competitor, Samsung, which holds only 7%. Despite this formidable position, a new challenger, Rapidus from Japan, is emerging with ambitions to mass-produce advanced 2nm chips, intending to offer them at a more competitive price than TSMC.

TSMC initiated the production of 2nm chips earlier this year, reportedly pricing them at $30,000 per wafer. In contrast, Rapidus, which is currently engaging with numerous companies, plans to launch its 2nm process in 2027 with a target price of approximately $21,000 per wafer. The critical question for investors is whether Rapidus can genuinely disrupt TSMC's market stronghold. TSMC's extensive history of innovation and its collaborative "open innovation platform" have enabled it to partner with clients on chip designs, resulting in the production of over 12,600 distinct products using 305 different process technologies in 2025 alone. The company's revenue from 3nm and 5nm chips has shown significant growth, with a reported first-quarter revenue of $35.9 billion, a 40.6% increase year-over-year, and a projected operating profit margin of 56.5% to 58.5%.

Rapidus, established in 2022 with the backing of the Japanese government, faces a substantial uphill battle against TSMC's entrenched dominance. Even established chip manufacturers like Samsung and Intel have struggled to capture significant market share from TSMC. Rapidus currently operates only a pilot line and plans to open a second fabrication plant next year. However, it still needs to demonstrate its ability to achieve large-scale manufacturing profitably. The company's management has already indicated that semiconductor prices are subject to various factors, including specifications and exchange rates, suggesting potential variability in their pricing strategy. Ultimately, major semiconductor companies prioritize reliability and high-quality production at scale over marginal price differences, making it unlikely they would switch suppliers from a proven leader like TSMC to a new entrant like Rapidus, especially since TSMC will have a significant head start in 2nm chip mass production.

TSMC's consistent innovation and industry leadership underscore the power of focused excellence and strategic partnerships. Companies that continuously push technological boundaries and cultivate strong relationships with their clients are poised for sustained success, even in the face of new competition. This narrative highlights the importance of innovation, reliability, and strategic foresight in navigating dynamic global markets, reinforcing the idea that true value extends beyond mere cost, fostering a competitive environment that ultimately benefits technological advancement and economic progress.

More Articles
Finance
POET Technologies: Overcoming Market Misconceptions and Scaling Production
Despite a significant stock price drop and past setbacks, POET Technologies has made substantial operational strides. The company is transitioning its focus from technology validation to large-scale manufacturing, backed by a $50 million expansion plan. New commercial deals, including an External Light Source agreement and numerous customer opportunities, are set to boost revenue. While traditional valuation metrics are skewed, the forward EV/Sales ratio has considerably decreased. The main challenge ahead is successfully scaling production in the coming quarters to realize future revenue growth.
By Robert KiyosakiJul 10, 2026
Finance
Tesla's Q2 Outlook: Unveiling Growth and Autonomy
This analysis delves into Tesla's robust Q2 performance projections, highlighting significant increases in deliveries, FSD subscriptions, and energy storage deployments. The company's unique autonomy-energy ecosystem, driven by vast driving data and innovative projects like Optimus, forms a formidable competitive edge. While acknowledging Tesla's exceptional status, the report suggests a cautious 'Hold' rating due to the stock's valuation, advocating for a portfolio cap to balance potential high returns with market dominance expectations.
By Michele FerreroJul 10, 2026
Finance
Medtronic: A Resilient Medtech Giant with Growth Potential
This article introduces Medtronic, a leading company in medical technology, highlighting its strong market position and attractive profit margins. It presents Medtronic as a promising opportunity for portfolio diversification, offering stable performance alongside expectations for increased revenue. The analysis suggests that Medtronic shares are currently undervalued, supporting a positive long-term investment outlook and a defensive strategy. A 'Buy' rating is assigned to MDT, acknowledging potential risks.
By Nouriel RoubiniJul 10, 2026
Finance
Leveraging SQQQ for Enhanced QQQ Portfolio Protection
This analysis delves into the strategic utilization of the ProShares UltraPro Short QQQ ETF (SQQQ) as a tool for hedging against potential downturns in a long QQQ position. While inherently volatile, SQQQ can be integrated to mitigate risk and potentially improve overall returns, emphasizing the critical role of precise timing and technical indicators for effective short-term market navigation.
By Suze OrmanJul 10, 2026
Finance
Viking Therapeutics: A Deep Dive into its GLP-1 Pipeline and Market Potential
Viking Therapeutics is making significant strides in its GLP-1 weight-loss drug development, with Phase 3 clinical trials underway for its injectable formulation and rapid progress on an oral version. Analyst price targets suggest substantial growth potential for the company. The current merger and acquisition activities within the biotech sector underscore the strong valuation prospects for Viking Therapeutics in the expanding GLP-1 market. The company's stock is considered attractive, with projected 2030 revenues of $1.3 billion and the potential to capture a substantial share of the estimated $190 billion GLP-1 market by 2035.
By Mariana MazzucatoJul 10, 2026